NuVasive Gains FDA Clearance for Pulse Surgical Automation
NuVasive received FDA 510(k) clearance to market Pulse surgical automation, the foundation for the company's Surgical Intelligence system. Jul 27, 2018
Stryker Posts 2Q18 Revenue Growth of 8% YoY
ORTHOWORLD estimates Stryker's 2Q18 orthopaedic revenue at US $1,747.8MM, +8.0% from 2Q17, and 1H18 revenue at $3,472.6MM, +7.5% vs. 1H17. Trauma and Extremities Joint Recon remain high performers, with Interventional and Tritanium products contributing to strong spine segment growth. Jul 27, 2018
DePuy Synthes Launches CONCORDE LIFT Expandable Interbody
DePuy Synthes commenced U.S. launch of the CONCORDE LIFT Expandable Interbody, part of the UNLEASH MIS TLIF Procedural Solution. Jul 26, 2018
Implanet Opens Subsidiary in Germany
Implanet established a subsidiary in Germany, furthering its strategy to expand sales in the European market. Jul 26, 2018
206 Ortho Granted US Patent for Biocompatible Composite
206 Ortho was issued a U.S. patent covering a new bio-inspired composite and implants that could fix broken bones without the need for implant removal. Jul 26, 2018
Smith & Nephew Issues Notice on First-Gen JOURNEY BCS
Smith & Nephew issued an Urgent Field Safety Notice affecting certain first-generation JOURNEY BCS components due to a higher than expected revision rate. Jul 24, 2018
FBC Device Gains FDA Clearance for Interbody Implant
FBC Device received its first FDA 510(k) clearance, granted for the FBC 921 ALIF interbody implant. Jul 24, 2018
DePuy Synthes Reports 2Q18 Orthopaedic Revenue -1.4% YoY
DePuy Synthes reported 2Q18 orthopaedic revenue of US $2,261.0MM, -1.4% vs. 2Q17, and 1H18 revenue of $4,511.0MM, -1.2% vs. 1H17. Jul 24, 2018
ReVivo Medical Efficacy Study Results
Results from an efficacy study of ReVivo Medical's spinal fusion technology demonstrated that loadsharing through elastic micro-motion accelerates bone formation and interbody fusion. Jul 23, 2018
Bioventus to Divest BMP Development to Viscogliosi Brothers
Bioventus entered into a definitive agreement to divest its next-gen bone morphogenetic protein development program to Viscogliosi Brothers. The transaction is slated to close in 3Q18. Jul 23, 2018
